Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) | Seeking Alpha
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Baclofen Tablets 20 mg by Teva 100 Count — Mountainside Medical Equipment